Characterization of Meta -Iodobenzylguanidine (mIBG) Transport by Polyspecific Organic Cation Transporters: Implication for mIBG Therapy.
Autor: | López Quiñones AJ; Department of Pharmaceutics, University of Washington, Seattle, Washington., Wagner DJ; Department of Pharmaceutics, University of Washington, Seattle, Washington., Wang J; Department of Pharmaceutics, University of Washington, Seattle, Washington jowang@uw.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | Molecular pharmacology [Mol Pharmacol] 2020 Aug; Vol. 98 (2), pp. 109-119. Date of Electronic Publication: 2020 Jun 02. |
DOI: | 10.1124/mol.120.119495 |
Abstrakt: | Radiolabeled meta -iodobenzylguanidine (mIBG) is an important radiopharmaceutical used in the diagnosis and treatment of neuroendocrine cancers. mIBG is known to enter tumor cells through the norepinephrine transporter. Whole-body scintigraphy has shown rapid mIBG elimination through the kidney and high accumulation in several normal tissues, but the underlying molecular mechanisms are unclear. Using transporter-expressing cell lines, we show that mIBG is an excellent substrate for human organic cation transporters 1-3 (hOCT1-3) and the multidrug and toxin extrusion proteins 1 and 2-K (hMATE1/2-K), but not for the renal organic anion transporter 1 and 3 (hOAT1/3). Kinetic analysis revealed that hOCT1, hOCT2, hOCT3, hMATE1, and hMATE2-K transport mIBG with similar apparent affinities ( K (Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.) |
Databáze: | MEDLINE |
Externí odkaz: |